Evidence map›Paper›PMID 39564427›Full record

ArticleJournal of clinical and experimental hepatology

Improved Outcomes of Liver Transplantation in Patients With Hepatitis C, Following the Introduction of Innovative Antiviral Therapies.

Mahmoudreza Moein, Peter Fioramonti, Kayla Lieb, Alireza Golkarieh, Artin Forouzan, Jessica Leipman, Amin Bahreini, Matin Moallem Shahri, Abolfazl Jamshidi, Reza Saidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mahmoudreza MoeinSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Peter FioramontiSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Kayla LiebSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Alireza GolkariehUniversity of Michigan, Department of Mechanical Engineering and Data Science, Ann Arbor, MI, USA.
Artin ForouzanSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Jessica LeipmanSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Amin BahreiniSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Matin Moallem ShahriSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Abolfazl JamshidiSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.
Reza SaidiSUNY Upstate Medical University, Division of Transplant Services, Department of Surgery, Syracuse, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The treatment landscape for hepatitis C virus (HCV) underwent a significant shift with the introduction of direct-acting antiviral (DAA) medications in late 2013. This study aimed to evaluate the impact of DAAs on liver transplantation outcomes, examining both the benefits and any potential drawbacks associated with their use. Methods and materials: A retrospective registry analysis of the United Network for Organ Sharing database was done for liver transplants in patients diagnosed with hepatitis C, that were performed in the United States from January 2000 to May 2020. Results: The study was divided into two subgroups, based on the timing of the new DAA medication that FDA approved. The only significant difference between the two cohorts is the recipient's age. The data analysis showed a significant overall 5-year graft survival improvement in the 2014-2020 group compared with the 2000-2013 group, from a mean of 64.8% in 2000-2013 to a mean of 76% in 2014-2020 ( Conclusion: The emergence of DAAs in 2013 marked a watershed moment in the management of HCV offering high cure rates, minimal side effects, and shorter treatment durations to a point that the short- and long-term outcomes of liver transplantation for HCV is almost equal to the other causes of liver transplantation.

Indexed as

allograft survivalhepatitis Cliver transplantationoutcomes

Identifiers

PMID39564427
PMCPMC11570942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.